235 related articles for article (PubMed ID: 33353406)
1. Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on the use of trabectedin.
Lorusso D; González-Martín A; Ray-Coquard I
Future Oncol; 2021 Jan; 17(3s):9-19. PubMed ID: 33353406
[TBL] [Abstract][Full Text] [Related]
2. Treatment of recurrent ovarian cancer.
Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
[TBL] [Abstract][Full Text] [Related]
3. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
Romero I; Mallol P; Santaballa A; Del Campo JM; Mori M; González-Santiago S; Casado A; Vicente D; Ortega E; Herrero A; Guerra E; Barretina-Ginesta P; Rubio MJ; Martínez A; Bover I; Vidal L; Arcusa Á; Martín L; García Y; González-Martín A
Anticancer Drugs; 2019 Jul; 30(6):628-635. PubMed ID: 31008727
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
Marth C
Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):19-22. PubMed ID: 30223697
[TBL] [Abstract][Full Text] [Related]
5. Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line.
Colombo N
Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):13-17. PubMed ID: 30223694
[TBL] [Abstract][Full Text] [Related]
6. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
7. GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
Selle F; Heudel PE; Hardy-Bessard AC; Pozet A; Meunier J; Gladieff L; Lotz JP; Provansal M; Augereau P; Berton D; Bonichon-Lamichhane N; Orfeuvre H; Pautier P; Kalbacher E; Tazi Y; Spaeth D
Anticancer Res; 2020 Jul; 40(7):3939-3945. PubMed ID: 32620635
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
Vertechy L; Boccia SM; Tiberi G; Avesani G; Corrado G; Fagotti A; Scambia G; Marchetti C
Int J Gynecol Cancer; 2023 Feb; 33(2):243-249. PubMed ID: 36564097
[TBL] [Abstract][Full Text] [Related]
9. When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer.
Colombo N
Future Oncol; 2017 Oct; 13(23s):23-29. PubMed ID: 29020821
[TBL] [Abstract][Full Text] [Related]
10. Management of relapsed ovarian cancer in routine clinical practice: a case study.
Ray-Coquard I
Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):9-11. PubMed ID: 30223695
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
Sehouli J; Alfaro V; González-Martín A
Ann Oncol; 2012 Mar; 23(3):556-562. PubMed ID: 21734221
[TBL] [Abstract][Full Text] [Related]
13. Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.
Colombo N; Hardy-Bessard AC; Ferrandina G; Marth C; Romero I
Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):11-19. PubMed ID: 27797622
[TBL] [Abstract][Full Text] [Related]
14. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
15. Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With
Lorusso D; Raspagliesi F; Ronzulli D; Valabrega G; Colombo N; Pisano C; Cassani C; Tognon G; Tamberi S; Mangili G; Mammoliti S; De Giorgi U; Greco F; Mosconi AM; Breda E; Artioli G; Andreetta C; Casanova C; Ceccherini R; Frassoldati A; Salutari V; Giolitto S; Scambia G
J Clin Oncol; 2024 May; 42(13):1488-1498. PubMed ID: 38315944
[TBL] [Abstract][Full Text] [Related]
16. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M
Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479
[TBL] [Abstract][Full Text] [Related]
17. The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Giuliani J; Bonetti A
Int J Gynecol Cancer; 2017 Nov; 27(9):1872-1876. PubMed ID: 28976446
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of chemotherapy according to
Brouillard-Saby F; Saint-Martin C; Ray-Coquard I; Gladieff L; Pomel C; Colombo PE; Classe JM; Chevrier M; Joly F; De la Motte Rouge T; Floquet A; Sabatier R; Barranger E; Costaz H; Leblanc E; Marchal F; Pautier P; Bosquet L; Rodrigues M
Int J Gynecol Cancer; 2023 Apr; 33(4):577-584. PubMed ID: 36631150
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421
[TBL] [Abstract][Full Text] [Related]
20. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
Erriquez J; Olivero M; Mittica G; Scalzo MS; Vaira M; De Simone M; Ponzone R; Katsaros D; Aglietta M; Calogero R; Di Renzo MF; Valabrega G
Oncotarget; 2016 May; 7(18):26181-91. PubMed ID: 27027433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]